P - Caution when used during pregnancy
L - Contraindicated in lactation
FI - Food *
Nateglinide is a drug for the treatment of type 2 diabetes. Nateglinide was developed by the Swiss pharmaceutical company Novartis.
Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Nateglinide, a nonsulfonylurea hypoglycaemic agent, acts by stimulating insulin release from pancreatic β-cells to reduce postprandial hyperglycaemia. This action depends on the amount of existing glucose levels.
Onset
Approx 20 minutes.
Duration
4 hours.
Absorption
Rapidly absorbed; peak plasma concentrations within 1 hour (oral).
Distribution
Protein-binding: 98%, primarily to albumin.
Metabolism
Hepatic via hydroxylation followed by glucuronidation; converted to metabolites.
Excretion
Via urine (16% unchanged drug); faeces (10%). Elimination half-life: 1.5 hours.
Information Not Available
Dizziness; back pain; arthropathy; upper respiratory tract infection; flu-like symptoms; bronchitis; cough; hypoglycaemia; accidental trauma; diarrhoea.
Information Not Available
Geriatric patients, debilitated and malnourished patients; adrenal or pituitary insufficiency, moderate to severe hepatic impairment; severe renal impairment. Monitor glycaemic levels during periods of stress. Pregnancy.
Increased levels/effects with enzyme inhibitors (e.g. fluconazole). Increased hypoglycaemic effects with salicylates, MAOIs, nonselective β-blockers, alcohol, NSAIDs. Decreased levels/effects with enzyme inducers (e.g. rifampicin). Decreased hypoglycaemic effects with thiazide diuretics, corticosteroids, thyroid products and sympathomimetic agents.
Food Interaction
Absorption delayed with food. Hypoglycaemic effects may be increased with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, American ginseng, gymnema, marshmallow and stinging nettle. Levels/effects may be reduced with St. John's wort.
Oral
Type 2 diabetes mellitus
Adult: 60-120 mg tid prior to each meal; may be increased to 180 mg tid if necessary.
Should be taken with food. (Take immediately before or up to ½ hour before meals.)
Caution when used during pregnancy
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Contraindicated in lactation
Safety and efficacy not established.
No differences were observed in safety or efficacy of Nateglinide between patients age 65 and over, and those under age 65. However, greater sensitivity of some older individuals to Nateglinide therapy cannot be ruled out.
Diabetic ketoacidosis; IDDM. Lactation.
Oral
Store at 25°C (77°F)
Oral
Store at 25°C (77°F)
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.